Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Cartesian Therapeutics Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters span 4 distinct examiners and 4 distinct art units, giving each action a separate examiner and technical examination context.
PARK, HAEJIN S is the busiest examiner, with 1 pending matter. Counsel should maintain a coordinated biotechnology position while preparing responses at the individual matter level.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARK, HAEJIN S | 1 | 55.1% | +38.3% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.2% | +38.9% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18828371 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | PAGUIO FRISING, MICHELLE F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18921868 | METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOCARRIERS WITH RAPAMYCIN IN A STABLE, SUPER-SATURATED STATE | PARK, HAEJIN S | — |
| 18828371 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | PAGUIO FRISING, MICHELLE F | — |
| 18818714 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | KIM, TAEYOON | — |
| 18654279 | ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS | BUNNER, BRIDGET E | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1651 | 1 |
| 1631 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18921868 | METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOCARRIERS WITH RAPAMYCIN IN A STABLE, SUPER-SATURATED STATE | PARK, HAEJIN S | 1614 | §103§112DP | Non-Final OA | — | Pending | Oct 21, 2024 |
| 18828371 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | PAGUIO FRISING, MICHELLE F | 1651 | §101§103DP | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18818714 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | KIM, TAEYOON | 1631 | §103Other | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18654279 | ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS | BUNNER, BRIDGET E | 1647 | Other | Non-Final OA | — | Pending | May 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCartesian Therapeutics Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Haejin S Park has the most, with 1 of Cartesian Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
